FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4247948062> ?p ?o ?g. }

• W4247948062 abstract "PreviousNext No AccessPrinciples of the Human Genome and PharmacogenomicsChapter 5. Pharmacogenetics Case Studieshttps://doi.org/10.21019/9781582121246.ch5 SectionsAboutFull TextReferences ToolsAdd to favoritesDownload CitationsTrack Citations ShareFacebookTwitterLinkedInRedditEmail Abstract: Learning Outcomes At the end of this chapter, you should be able to: 1.Outline and discuss the importance of environmental responses and their potential impact on pharmacogenetic studies of drug response and disposition. 2.Discuss two critical properties that must be present if pharmacogenetics is to play a key role in optimizing patient care for a specific therapeutic agent. 3.Predict whether pharmacogenetics may play a key role in optimizing the desired response with a specific drug based on knowledge of the mechanism of action, metabolic or transport properties, and types of gene variants or haplotypes involved in the pharmacological effect and disposition.References1. Lindpaintner K. Pharmacogenetics and pharmacogenomics in drug discovery and development: an overview. Clin Chem Lab Med. 2003;41:398–410. Crossref, Medline, Google Scholar, 2. Kalow W. Human pharmacogenomics: the development of a science. Hum Genomics. 2004;1:375–80. Crossref, Medline, Google Scholar, 3. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov. 2004;3:739–48. Crossref, Medline, Google Scholar, 4. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther. 2005;107:155–76. Crossref, Medline, Google Scholar, 5. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13–33. Crossref, Medline, Google Scholar, 6. Nebert DW, Vesell ES. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol. 2004;500:267–80. Crossref, Medline, Google Scholar, 7. Nebert DW, Jorge-Nebert L, Vesell ES. Pharmacogenomics and “individualized drug therapy”: high expectations and disappointing achievements. Am J Pharmacogenomics. 2003;3:361–70. Crossref, Medline, Google Scholar, 8. Nebert DW, Vesell ES. Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol Sci. 2006;27:580–6. Crossref, Medline, Google Scholar, 9. Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J. 2006;6:16–21. Crossref, Medline, Google Scholar, 10. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev. 2008;40:187–224. Crossref, Medline, Google Scholar, 11. Transon C, Leeman T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50:201–15. Crossref, Google Scholar, 12. Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics. 1997;7:375–9. Crossref, Medline, Google Scholar, 13. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329–39. Crossref, Medline, Google Scholar, 14. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651–62. Medline, Google Scholar, 15. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res. 1999;16:342–9. Crossref, Medline, Google Scholar, 16. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene. 2006;25:1629–38. Crossref, Medline, Google Scholar, 17. Tai H-L, Krynetski EY, Schuetz EG, et al. Enhanced proteolysis of thiopurine S-methyl-transferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA. 1997;94:6444–9. Google Scholar, 18. Krynetski EY, Fessing MY, Yates CR, et al. Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library. Pharm Res. 1997;14:1672–8. Crossref, Medline, Google Scholar, 19. Wang L, Sullivan W, Toft D, et al. Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics. 2003;13:555–64. Crossref, Medline, Google Scholar, 20. van Aken J, Schmedders M, Feuerstein G, et al. Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am J Pharmacogenomics. 2003;3:149–55. Crossref, Medline, Google Scholar, 21. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1—rationale and perspectives. Thromb Res. 2007;120:1–10. Crossref, Medline, Google Scholar, 22. Geisen C, Watzka M, Sittinger K, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005;94:773–9. Medline, Google Scholar, 23. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106–12. Crossref, Medline, Google Scholar, PreviousNext Session Activity Recently Viewed Chapter 5. Pharmacogenetics Case Studies Daniel A. Brazeau and Gayle A. Brazeau Recently Searched No search history FiguresReferencesRelatedDetails Published: 8 June 2016eISBN: 1-58212-124-9 Copyright & Permissions© 2011 by the American Pharmacists Association. All rights reserved.© 2011 by the American Pharmacists Association. All rights reserved. Publisher American Pharmacists Association HistoryPublished: 8 June 2016 Citation Information (2011), Chapter 5. Pharmacogenetics Case Studies, Principles of the Human Genome and Pharmacogenomics https://doi.org/10.21019/9781582121246.ch5 Loading ..." @default.
• W4247948062 created "2022-05-12" @default.
• W4247948062 date "2011-01-01" @default.
• W4247948062 modified "2023-09-26" @default.
• W4247948062 title "Chapter 5. Pharmacogenetics Case Studies" @default.
• W4247948062 cites W1252407659 @default.
• W4247948062 cites W1967490229 @default.
• W4247948062 cites W196869739 @default.
• W4247948062 cites W1977280638 @default.
• W4247948062 cites W1985661112 @default.
• W4247948062 cites W1988658163 @default.
• W4247948062 cites W199358782 @default.
• W4247948062 cites W2006484761 @default.
• W4247948062 cites W2024914385 @default.
• W4247948062 cites W2040579290 @default.
• W4247948062 cites W2045176691 @default.
• W4247948062 cites W2074022399 @default.
• W4247948062 cites W2077219824 @default.
• W4247948062 cites W2079373943 @default.
• W4247948062 cites W2084815355 @default.
• W4247948062 cites W2086662420 @default.
• W4247948062 cites W2089372668 @default.
• W4247948062 cites W2139452536 @default.
• W4247948062 cites W2140877639 @default.
• W4247948062 cites W2163636362 @default.
• W4247948062 cites W2270814902 @default.
• W4247948062 doi "https://doi.org/10.21019/9781582121246.ch5" @default.
• W4247948062 hasPublicationYear "2011" @default.
• W4247948062 type Work @default.
• W4247948062 citedByCount "0" @default.
• W4247948062 crossrefType "book-chapter" @default.
• W4247948062 hasConcept C104317684 @default.
• W4247948062 hasConcept C135763542 @default.
• W4247948062 hasConcept C170734499 @default.
• W4247948062 hasConcept C2779473830 @default.
• W4247948062 hasConcept C54355233 @default.
• W4247948062 hasConcept C55493867 @default.
• W4247948062 hasConcept C55775858 @default.
• W4247948062 hasConcept C60644358 @default.
• W4247948062 hasConcept C71924100 @default.
• W4247948062 hasConcept C86803240 @default.
• W4247948062 hasConcept C98274493 @default.
• W4247948062 hasConceptScore W4247948062C104317684 @default.
• W4247948062 hasConceptScore W4247948062C135763542 @default.
• W4247948062 hasConceptScore W4247948062C170734499 @default.
• W4247948062 hasConceptScore W4247948062C2779473830 @default.
• W4247948062 hasConceptScore W4247948062C54355233 @default.
• W4247948062 hasConceptScore W4247948062C55493867 @default.
• W4247948062 hasConceptScore W4247948062C55775858 @default.
• W4247948062 hasConceptScore W4247948062C60644358 @default.
• W4247948062 hasConceptScore W4247948062C71924100 @default.
• W4247948062 hasConceptScore W4247948062C86803240 @default.
• W4247948062 hasConceptScore W4247948062C98274493 @default.
• W4247948062 hasLocation W42479480621 @default.
• W4247948062 hasOpenAccess W4247948062 @default.
• W4247948062 hasPrimaryLocation W42479480621 @default.
• W4247948062 hasRelatedWork W149399689 @default.
• W4247948062 hasRelatedWork W1984239800 @default.
• W4247948062 hasRelatedWork W1986027462 @default.
• W4247948062 hasRelatedWork W2025838170 @default.
• W4247948062 hasRelatedWork W2087462834 @default.
• W4247948062 hasRelatedWork W2115976912 @default.
• W4247948062 hasRelatedWork W2125288555 @default.
• W4247948062 hasRelatedWork W2941058775 @default.
• W4247948062 hasRelatedWork W3039677249 @default.
• W4247948062 hasRelatedWork W48912384 @default.
• W4247948062 isParatext "false" @default.
• W4247948062 isRetracted "false" @default.
• W4247948062 workType "book-chapter" @default.